Overview

Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis

Status:
NOT_YET_RECRUITING
Trial end date:
2028-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to assess the effectiveness of two treatment strategies for smoking cessation in patients with acute recurrent pancreatitis or chronic pancreatitis who smoke cigarettes. All participants will receive varenicline, a commonly used medication that helps people stop smoking, at its standard dose. For those who are unable to stop smoking after 6 weeks of treatment, they will be randomly selected to either 1) increase their dose of varenicline, 2) combine varenicline with bupropion (another medication that helps with smoking cessation) or continue on the standard dose of varenicline. At the end of 12 weeks of treatment, participants will be asked if they have stopped smoking with confirmation done by measuring carbon monoxide levels in their breath.
Phase:
PHASE2
Details
Lead Sponsor:
Mayo Clinic
Treatments:
BID protein, human
Bupropion